Supplementary Figure S2 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy

Figure S2. (A) Distribution of clonal hematopoiesis (CH) among the 90 patients with evaluable NGS, divided by low (<300 ng/mL) or high (≥300 ng/mL) baseline ferritin at the time of CAR-T infusion. (B) CH patients by number of CH-associated mutations. (C-E) Time to sustained myeloid recovery stratified by pre-existing CH (C), by the 4 most common CH mutations (D), or by both baseline ferritin (ferr.) and CH (E), with medians and hazard ratio (HR) with 95% confidence intervals (CI) shown.